拉米夫定 复方甘草酸苷治疗乙肝成本-效果分析  

Comparision of Therapeutic Effects and Cost effectiveness Analysis of Lamivudine and Compound Glycyrrhizin for Chronic Hepatitis B

作　　者：杨诗杰[1] 吴进军[1] 蔡定彬[1] 王娜[1] 苏汝好[1] 

机构地区：[1]广东医学院附属医院,湛江市524001

出　　处：《医药论坛杂志》2006年第2期24-25,共2页Journal of Medical Forum

基　　金：广东省科技攻关项目(项目编号:A98040)

摘　　要：目的评价拉米夫定与复方甘草酸苷两种方案治疗慢性乙型肝炎的临床疗效及所产生的经济效果。方法运用药物经济学成本-效果分析方法对72例慢性乙型肝炎的治疗(拉米夫定治疗为A方案,复方甘草酸治疗为B方案)进行回顾性分析评价。结果两组治疗方案在ALT复常率、HBeAg、HBV-DNA转阴率方面虽有差异但无统计学意义(P>0.05)。B方案达到一个效果单位所花费成本最低。结论在其他因素相同情况下,应优先选择B方案。Objective To evaluate the clinical efficacy and the economic effectiveness of lamivudine and compound glycyrrhizin for chronic hepatitis B. Methods Using pharmaconomical cost-effectiveness analysis, two therapeutic schemes （ scheme A of lamivadine and scheme B of compound glycyrrhinin） for 72 chronic hepatitis B, were retrospectivly evaluated. Results In unit effect of decreasing ALT, HBeAg,HBV - DNA negative conversion, the ratio of groupB and groupA （82.76% and 76%, respectively） were different but not statistically significant. By pharmaconomical cost-effectiveness analysis,the expenses of group B cost in the similar effect was lowest. Conclusion The therapeutic scheme B for chronic hepatitis B should be chosed preferentially.

关 键 词：慢性乙型肝炎 成本-效果分析 拉米夫定 复方甘草酸苷 

分 类 号：R512.62[医药卫生—内科学]